6831-55-6

Basic information

• Product Name: (3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE
• Synonyms: (3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE;2-(3,4-dichlorophenyl)acetyl chloride
• CAS NO: 6831-55-6
• Molecular Formula: C₈H₅Cl₃O
• Molecular Weight: 223.48
• Mol File: 6831-55-6.mol
• Article Data: 48

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE(6831-55-6)
• EPA Substance Registry System: (3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE(6831-55-6)

Safety Data

• Hazardous Substances Data: 6831-55-6(Hazardous Substances Data)

Usage

General Description

(3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE is a chemical compound with the molecular formula C8H6Cl2O. It is an acetyl chloride derivative of 3,4-dichlorophenyl, a synthetic compound used in the production of various pharmaceuticals and agrochemicals. (3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE is commonly used in organic synthesis as a reagent for introducing the acetyl functional group into various organic molecules. It is a colorless to pale yellow liquid with a pungent odor, and it is highly reactive, making it important to handle with caution in a controlled laboratory setting. (3,4-DICHLORO-PHENYL)-ACETYL CHLORIDE is a valuable building block in the production of many different chemical products.

Upstream product

• 5807-30-7 3,4-dichlorophenyl acetic acid 
• 106-46-7 para-dichlorobenzene 
• 79-04-9 chloroacetyl chloride 
• 1805-32-9 3,4-dichlorobenzyl alcohol 
• 23722-52-3 2-diazo-1-(3,4-dichlorophenyl)ethan-1-one 
• 3024-72-4 3,4-dichlorobenzoyl chloride 
• 3218-49-3 3,4-dichloro-benzeneacetonitrile 
• 79-37-8 oxalyl dichloride 
• 18880-04-1 3,4-dichlorobenzyl bromide 
• 121639-61-0 3,4-difluorophenylacetyl chloride 
• 51-44-5 3,4-dichlorbenzoic acid 

Downstream Products

• 130109-48-7 2-(3,4-dichlorophenyl)-N-methyl-N-<(1R,S)-1-(4-nitrophenyl)-2-(1-pyrrolidinyl)ethyl>acetamide 
• 229157-43-1 2-(3,4-dichloro-phenyl)-N-[2-(5-methoxy-benzofuran-3-yl)-ethyl]-acetamide 
• 467443-39-6 2-[3-(3,4-dichloro-benzyl)-2,4,5-trioxo-imidazolidin-1-yl]-propionic acid ethyl ester 
• 467443-13-6 1-[3-(3,4-dichloro-benzyl)-ureido]-cyclohexanecarboxylic acid ethyl ester 
• 467443-23-8 1-[3-(3,4-dichloro-benzyl)-ureido]-cyclohexanecarboxylic acid benzyl ester 
• 467443-31-8 1-[3-(3,4-dichloro-benzyl)-2,4,5-trioxo-imidazolidin-1-yl]-cyclohexanecarboxylic acid benzyl ester 
• 366456-45-3 N-(4-amino-2-benzoylphenyl)-2-(3,4-dichlorphenyl)acetamide 
• 366456-59-9 N-[3-benzoyl-4-[2-(3,4-dichlorophenyl)acetylamino]phenyl]-N^α-tert-butyloxycarbonyl-S-tritylcysteinamide 

Relevant articles and documents

Pentuline derivatives and preparation methods and applications thereof

The present invention provides a chingotine derivative, the structural formula of which is shown in formula I. Specifically, the R is any of the following groups: p-chlorophenylacetyl, 2,4-dichlorophenylacetyl, m-chlorophenylacetyl, 3,4-dichlorophenylacet

Design, synthesis, biological evaluation and silico prediction of novel sinomenine derivatives

Sinomenine is a morphinan alkaloid with a variety of biological activities. Its derivatives have shown significant cytotoxic activity against different cancer cell lines in many studies. In this study, two series of sinomenine derivatives were designed and synthesized by modifying the active positions C1 and C4 on the A ring of sinomenine. Twenty‐three compounds were synthesized and characterized by spectroscopy (IR,1H‐NMR,13C‐NMR, and HRMS). They were further evaluated for their cytotoxic activity against five cancer cell lines, MCF‐7, Hela, HepG2, SW480 and A549, and a normal cell line, Hek293, using MTT and CCK8 methods. The chlorine‐containing compounds exhibited significant cytotoxic activity compared to the nucleus structure of sinomenine. Furthermore, we searched for cancer‐related core targets and verified their interaction with derivatives through molecular docking. The chlorine‐containing compounds 5g, 5i, 5j, 6a, 6d, 6e, and 6g exhibited the best against four core targets AKT1, EGFR, HARS and KARS. The molecular docking results were consistent with the cytotoxic results. Overall, results indicate that chlorine‐containing derivatives might be a promising lead for the development of new anticancer agents.

N-monoarylacetothioureas as potent urease inhibitors: synthesis, SAR, and biological evaluation

A urease inhibitor with good in vivo profile is considered as an alternative agent for treating infections caused by urease-producing bacteria such as Helicobacter pylori. Here, we report a series of N-monosubstituted thioureas, which act as effective urease inhibitors with very low cytotoxicity. One compound (b19) was evaluated in detail and shows promising features for further development as an agent to treat H. pylori caused diseases. Excellent values for the inhibition of b19 against both extracted urease and urease in intact cell were observed, which shows IC50 values of 0.16 ± 0.05 and 3.86 ± 0.10 μM, being 170- and 44-fold more potent than the clinically used drug AHA, respectively. Docking simulations suggested that the monosubstituted thiourea moiety penetrates urea binding site. In addition, b19 is a rapid and reversible urease inhibitor, and displays nM affinity to urease with very slow dissociation (koff=1.60 × 10?3 s?1) from the catalytic domain.